StreetInsider.com News Articles

Hyperfine reports 3,000 scans and study results in office MRI push

Wed, 26 Aug 2026 08:16:13 -0400

Hyperfine, Inc. (Nasdaq: HYPR) announced the peer-reviewed publication of the NEURO PMR study in the Journal of Neuroimaging, alongside a milestone of more than 3,000 brain MRI scans completed in outpatient settings during the first year of its office-market launch.

The NEURO PMR study, described as the first prospective, multicenter, real-world study comparing portable MRI to high-field MRI in outpatient neurology clinics, found that portable MRI demonstrated 92% concordance with high-field MRI in identifying the presence or absence of structural abnormality in blinded neuroradiology review, rising to 98% when clinical information was included. Patients reported preferring portable MRI over high-field MRI

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Wed, 26 Aug 2026 08:15:00 -0400

Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the peer-reviewed publication of the NEURO PMR study in the Journal of Neuroimaging. The publication comes as real-world use of the Swoop system continues to grow, with more than 3,000 brain MRI scans completed across a broad range of physician practices within the first

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Wed, 26 Aug 2026 08:15:00 -0400

Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Wed, 26 Aug 2026 08:15:00 -0400

Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Wed, 26 Aug 2026 08:15:00 -0400

Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Wed, 26 Aug 2026 08:15:00 -0400

Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Wed, 26 Aug 2026 08:15:00 -0400

Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Wed, 26 Aug 2026 08:15:00 -0400

Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Wed, 26 Aug 2026 08:15:00 -0400

Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

Form 4 Hyperfine, Inc. For: Aug 24 Filed by: TEISSEYRE THOMAS

Tue, 25 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260825/26974927.html

Form 4 Hyperfine, Inc. For: Aug 24 Filed by: TEISSEYRE THOMAS

Tue, 25 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260825/26974927.html

Form 4 Hyperfine, Inc. For: Aug 24 Filed by: HALE BRETT

Tue, 25 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260825/26974893.html

Form 4 Hyperfine, Inc. For: Aug 24 Filed by: HALE BRETT

Tue, 25 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260825/26974893.html

BTIG Reiterates Buy Rating on Hyperfine Inc. (HYPR)

Thu, 20 Aug 2026 09:07:33 -0400

BTIG analyst Marie Thibault reiterated a Buy rating and $2.00 price target on Hyperfine Inc. (NASDAQ: HYPR).

The analyst commented: "This morning, Hyperfine announced it has received FDA clearance for its latest Optive AI software update. This is HYPR's second FDA-cleared software package since the mid-2025 launch of its next-generation Swoop System and is in line with the company's committed cadence of 1-2 FDA-cleared AI software releases each year. The software update enhances image quality, improves the user interface, and introduces a new sequence that enables isotropic imaging for three-dimensional visualization. With this update, the company's proprietary noise cancellation feature is

Hyperfine wins FDA clearance for updated portable MRI software

Thu, 20 Aug 2026 08:15:35 -0400

Hyperfine, Inc. (Nasdaq: HYPR) has received FDA clearance for a new version of its Optive AI software, which runs on the company's Swoop portable MRI system designed for brain imaging.

According to a press release from the Guilford, Connecticut-based company, this is the second FDA-cleared software package released since the Swoop system's next-generation launch in mid-2025. The updated software includes improved noise correction across all imaging sequences, a redesigned user interface with a guided scanning workflow, and the ability to view sequences and images during acquisition.

The update also introduces an isotropic T1 sequence, which delivers thinner slices and uniform resolution across

Hyperfine wins FDA clearance for updated portable MRI software

Thu, 20 Aug 2026 08:15:35 -0400

Hyperfine, Inc. (Nasdaq: HYPR) has received FDA clearance for a new version of its Optive AI software, which runs on the company's Swoop portable MRI system designed for brain imaging.

The update also introduces an isotropic T1 sequence, which delivers thinner slices and uniform resolution across

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings